You are here

Article info

Article menu
Download PDFPDF
Editorial commentary
Guidelines on PML risk stratification and diagnosis in patients with MS treated with natalizumab: so far so good?

Authors

  • Mike P Wattjes MS Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Clemens Warnke Department of Neurology, Medical Faculty, Heinrich Heine University Hospital, Düsseldorf, Germany PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Mike P Wattjes, Department of Radiology & Nuclear Medicine, MS Center Amsterdam, VU University Medical Center, De Boelelaan 1117, Amsterdam 1081 HV, The Netherlands; m.wattjes{at}vumc.nl
View Full Text

Citation

Wattjes MP, Warnke C
Guidelines on PML risk stratification and diagnosis in patients with MS treated with natalizumab: so far so good?
Journal of Neurology, Neurosurgery & Psychiatry 2016;87:115.

Publication history

  • Received July 20, 2015
  • Accepted August 3, 2015
  • First published October 22, 2015.
Online issue publication 
April 13, 2016

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/